Titlebook: Antifolate Drugs in Cancer Therapy; Ann L. Jackman Book 1999 Springer Science+Business Media New York 1999 biochemistry.cancer.cancer ther

使成波狀

弄污

興奮過度

Receptor- and Carrier-Mediated Transport Systems for Folates and Antifolates,reductase (DHFR) (.). More recently, folate analogs were synthesized that could target other key enzymes in folate metabolism, including thymidylate synthase (TS) (., .) glycinamide ribonucleotide transformylase (GARTFase) (., .) and folylpolyglutamate synthetase (FPGS) (.). A number of these novel

大火

Folates as Chemotherapeutic Modulators,ity in several epithelial malignancies (.–.). The rational use of folates as modulators of toxicity or antitumor activity requires an integral understanding of their biochemistry, pharmacokinetics, and pharmacodynamics.

Intellectual

多骨

Folate Biochemistry in Relation to Antifolate Selectivity,s of folate metabolism, alterations in the activity of any folate enzyme, cellular transport system, as well as the concentration of any folate metabolite may be relevant to antifolate cytotoxicity and selectivity. Therefore, it is difficult to predict the results of inhibiting a given folate enzyme

CLASH

Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors,LL), was first tested .. Methotrexate (MTX), also an antifolate inhibitor of dihydrofolate reductase (DHFR), soon after replaced aminopterin in the clinic and is used widely not only for the treatment of various forms of cancer, such as lymphoma, germ-cell tumors, breast cancer, and head and neck ca

Vertical

Development of Nonpolyglutamatable DHFR Inhibitors,TX, .) were found to induce temporary remission in children with acute leukemia .. In the five decades that followed this landmark in the history of chemotherapy ., the term “an-tifolate” or “antifol” has come to refer not only to inhibitors of DHFR but also to in-hibitors of other enzymes of one-ca

文藝

Fluoropyrimidines as Antifolate Drugs,ombination with other agents for the treatment of various types of cancer . such as cancers of the gas-trointestinal tract, breast cancer, and head and neck cancer. For combinations of leucov-orin (LV) and 5FU objective response rates between 20 and 40% have been achieved in randomized trials in pat

Lime石灰